Novo Nordisk stock steadies as Q2 2026 outlook is raised and obesity pipeline advances

Novo Nordisk A/S stock (ISIN DK0062498333) is trading steadily in late August 2026 as the Danish drug maker digests a stronger adjusted profit performance in the second quarter of 2026, a raised full-year outlook and a fresh obesity pipeline milestone tied to the oral candidate LX9851 as of August 24, 2026.

Q2 2026 figures and upgraded outlook

Per a recent earnings overview, Novo Nordisk reported second-quarter 2026 adjusted sales of DKK 78,488 million, with growth of 7% at constant exchange rates compared with the prior-year period. A detailed Q2 2026 summary notes that adjusted operating profit reached DKK 33,389 million in the quarter, rising 11% at constant exchange rates versus the same quarter of 2025, helped by GLP-1 volume growth and favorable rebate dynamics.

The same Q2 2026 review indicates that on a non-adjusted basis, operating profit was pressured by one-off items including DKK 6.3 billion in non-cash impairments to intangible pipeline assets, showing how the headline decline in reported operating profit masks a healthier underlying trajectory. In contrast, the adjusted figures provide a cleaner view of ongoing profitability trends in the core diabetes and obesity franchises.

For full-year 2026, Novo Nordisk has now guided adjusted sales growth at constant exchange rates to a range of 0% to -6%, improved from a previous band of -4% to -12%. The company has also raised its outlook for adjusted operating profit growth in 2026 to the same 0% to -6% range, from an earlier indication of -4% to -12%, suggesting management expects moderately better performance than initially planned.

The Q2 2026 guidance discussion adds that on a non-adjusted basis the mid-points of the 2026 sales and operating profit growth guidance at constant exchange rates would be 5% and 12%, respectively, illustrating that the bridge from adjusted to reported results depends heavily on the treatment of pipeline-related impairments and prior-year rebate effects rather than ongoing business weakness.

Analyst stance and recent share performance

Market data compiled for Novo Nordisk shows that the company’s Copenhagen-listed shares last closed at DKK 299.25 on August 24, 2026, on the Nasdaq Copenhagen exchange, reflecting a five-day variation that modestly softened but a year-to-date change of 2.34% in positive territory. A recent trading snapshot also highlights that the average target price for Novo Nordisk shares stands at DKK 309.73, implying upside versus the latest closing price level.

Within that targeting context, one analyst note cited in the same trading overview points to a new individual price objective of DKK 275 for Novo Nordisk shares, lifted from a prior DKK 250 level, while keeping a neutral rating stance. Although this particular target of DKK 275 sits below the current market price of DKK 299.25, the broader average price target of DKK 309.73 remains above the latest close, underscoring that the consensus still sees room for moderate appreciation from present levels.

On the German Tradegate venue, Novo Nordisk’s NOVA listing last closed at EUR 40.24 on August 24, 2026, with a daily gain of 0.55% and a five-day progression that saw closes of EUR 39.50, EUR 39.80, EUR 39.54, EUR 40.02 and EUR 40.24 from August 18 to August 24, 2026. The same data overview indicates that the Tradegate listing’s year-to-date variation stands at 0.91% and a performance of -9.15% over a longer comparative horizon, revealing a more muted performance profile than the Copenhagen line despite similar underlying fundamentals.

For investors comparing platforms, the divergence between the Copenhagen close at DKK 299.25 and the Tradegate close at EUR 40.24 reflects currency translation, liquidity differences and the impact of local investor demand, but both listings broadly confirm that Novo Nordisk shares are consolidating rather than trending aggressively in either direction as of late August 2026.

Obesity pipeline milestone with LX9851

Beyond the headline diabetes and injectable obesity treatments, Novo Nordisk is also progressing an oral obesity drug candidate, LX9851, developed in collaboration with Lexicon Pharmaceuticals. A recent collaboration update describes how a key clinical milestone in the development of LX9851 was reached, triggering a milestone payment to Lexicon tied to progress in treating obesity and related metabolic disorders.

In a further analysis of the collaboration economics, a detailed report on the LX9851 trial explains that Lexicon received a $10 million milestone payment from Novo Nordisk on August 24, 2026, after reaching a patient-dosing milestone in the Phase 1 study of LX9851. This payment lifts cumulative collaboration earnings for Lexicon to $75 million and sits within a broader framework that could exceed $1 billion in future milestones plus royalties if the candidate progresses successfully.

The LX9851 program represents a first-in-class oral obesity drug with a non-incretin mechanism of action, complementing Novo Nordisk’s existing GLP-1 based treatments for obesity and diabetes. The addition of an oral, non-incretin therapy could expand the addressable patient population, especially for individuals who prefer tablets over injections or respond differently to GLP-1 pathways, reinforcing Novo Nordisk’s ambition to build a diversified, multi-mechanism obesity portfolio.

In a broader competitive discussion of the obesity market, a recent feature on the weight-loss drug landscape cites comments made on August 13, 2026 by Novo Nordisk’s leadership arguing that investors are underestimating how much the obesity market will fragment over time as new mechanisms and delivery formats enter the field. The advancement of an oral non-incretin candidate like LX9851 fits that thesis, offering a different mode of action from existing injectable GLP-1 therapies and highlighting why Novo Nordisk is investing across multiple pathways.

Competitive GLP-1 backdrop

The pipeline efforts around LX9851 unfold against an increasingly crowded GLP-1 and obesity treatment backdrop, with rival offerings gaining regulatory traction in key markets. A recent competitive update points out that Eli Lilly’s GLP-1 pill, Foundayo, has now reached pharmacies in the United Kingdom for weight management and type 2 diabetes, making that country the first in Europe to authorize the tablet for both indications.

The same competitive overview notes that a tracking study observed Novo Nordisk’s Wegovy franchise holding broadly flat in mid-August 2026, with weekly prescription volumes rising 3% in the seven days to August 14 but remaining flat on a four-week rolling basis. In contrast, Foundayo captured 36,620 US prescriptions in that period, declining 6% week on week after a 14% gain the week before, while Novo Nordisk’s Wegovy pill recorded 137,333 prescriptions in the equivalent 18th full week of its own launch, highlighting that Novo Nordisk still maintains a sizable lead in prescription volumes despite the new competition.

The prescription comparison illustrates a key quantified competitive delta: Wegovy’s 137,333 prescriptions in that reference week exceeded Foundayo’s 36,620 prescriptions by a factor of more than three, confirming that Novo Nordisk currently commands a dominant share in the early GLP-1 tablet obesity segment. However, the evolving trend lines also suggest that the market is dynamic and that newer entrants can gain ground quickly, reinforcing the importance of Novo Nordisk’s efforts to diversify its pipeline with candidates like LX9851 and to defend its franchise through both innovation and legal channels.

On the legal front, Novo Nordisk has taken steps to challenge what it views as misleading advertising linked to GLP-1 therapies. An explainer on a recent GLP-1 advertising dispute recounts that Novo Nordisk sent a cease-and-desist request before filing suit to stop multiple national GLP-1 campaigns and is seeking a permanent injunction to remove disputed advertising and run a corrective campaign, with a preliminary injunction request expected prior to full case resolution.

Representative product: Wegovy obesity treatment

One of Novo Nordisk’s flagship obesity products is Wegovy, a semaglutide-based treatment that leverages the GLP-1 pathway to help patients reduce body weight. Wegovy has been launched as both an injectable and a pill in certain markets, targeting adults with obesity or overweight who face weight-related comorbidities such as type 2 diabetes or cardiovascular risk factors.

The treatment works by mimicking the action of the human glucagon-like peptide-1 hormone, which regulates appetite and food intake, helping patients feel fuller sooner and reduce calorie consumption. Clinical studies have shown substantial average weight loss among patients using Wegovy alongside lifestyle interventions, supporting its adoption as a cornerstone therapy in the modern obesity care toolkit.

As with all GLP-1 based therapies, Wegovy’s risk-benefit profile requires careful assessment of side effects such as gastrointestinal symptoms and the need for long-term adherence to maintain results. For Novo Nordisk, Wegovy represents both a commercial driver and a platform on which to build next-generation obesity treatments, including oral options and non-incretin mechanisms like LX9851.

Stock context and closing view

Based on recent market data, Novo Nordisk’s NOVA listing on the Tradegate platform closed at EUR 40.24 on August 24, 2026, with a daily gain of 0.55% and a year-to-date performance of 0.91% at that venue, while its Copenhagen-listed shares closed at DKK 299.25 on the same date, reflecting a modest positive year-to-date change of 2.34%. These price levels position Novo Nordisk stock slightly below the average analyst target of DKK 309.73, suggesting that consensus expectations allow some upside compared with current trading ranges.

For retail investors, the key narrative now combines the solid adjusted Q2 2026 profit growth of 11% at constant exchange rates, the improved full-year 2026 guidance for both adjusted sales and operating profit, and the strategic push into oral and non-incretin obesity drugs like LX9851 alongside the established Wegovy franchise. Novo Nordisk stock thus reflects a balance between consolidating share performance and ongoing investment in obesity and diabetes innovation, within a competitive GLP-1 landscape that continues to evolve rapidly.

Fact box

Company: Novo Nordisk A/S

ISIN: DK0062498333

Ticker: NOVO B (Copenhagen), NOVA (Tradegate)

Exchange: Nasdaq Copenhagen, Tradegate

Price (as of August 24, 2026, Copenhagen close): DKK 299.25

Price (as of August 24, 2026, Tradegate close): EUR 40.24

Sector / Industry: Healthcare / Pharmaceuticals

Index membership: Key Danish and European indices